Port,Let me addressed each of the bull you posted:Quote: 1)...

Port,

Let me addressed each of the bull you posted:
Quote: 1) Share buyback - Indicates they are not just there to build empires and have shareholders in mind;
The share buy back was conducted to support the sp so that Peter Cook could continue reaping free share options.
It was conducted in the most unsatisfactorily manner where on days BTA bought up to 90% of the turn-over.
In any case the share bought back had been negated by Peter Cook free options.
The parasites now have control of more than 2% of the company shares excluding options.

2) Capital return in tax effective mannor;
The idiots run the company with losses year after year and as a result has a build up of collosal losses.
Hence the company has no capacity to pay frank dividents forcing it to return capital instead.
Only the idiot Peter Cook call this a success. Port I am surprise you did not post that it is most tax effective to shareholders when the money BTA used to buy shares back for the options vested to Peter Cook - shareholders dont worry about paying tax, do they?

3) Successful completion of HRV phase IIa trial;
HRV has a long way to go before commercialisation.

4) Successful completion of LANI Phase III trials in Asia;
Peter Molloy launched the LANI trials and the Daiichi Sankyo partnership long before Peter Cook the idiot crept into BTA. It is shameful to claim this as Peter Cooks success - he had not launch a single trial or development of LANI - just sat on his hands and claimed Peter Molloy's credit!

5) GSK increasing Relenza production (I wonder if they would have done this with a threat of a half billion dollar law case against them?)
When the law suit was on, GSK was forced to increase production by Government orders to capture 10% of the antiviral market limited only by production capacity.
At the end of August 2009, Relenza share of the antiviral market fell back to 10%, limited only by production. Port, it is plainly dishonest to mimic Peter Cook's LIES that the settlement is the reason for the increased Relenza sales.


6) Desire to expand by concentrating of what they do best i.e. early stage drug development
Despite increasing R&D spending to 130% of last financial year, Peter Cook had milestone revenue dropping to ZERO. What a great success.